What is Citius Oncology, Inc.'s gross profit?

Citius Oncology, Inc. (CTOR) reported gross profit of $1.34M in Q1 2026.

What does gross profit mean?

Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.

Citius Oncology, Inc. CTOR Gross Profit

Gross Profit at other companies

Merck & Co.MRK

$12.09B-0.2%

Delcath SystemsDCTH

$21.26M+25.5%

Iovance Biotherapeutics, Inc.IOVA

$28.93M+338%

Nektar TherapeuticsNKTR

$21.81M+2.9%

Gilead SciencesGILD

$5.52B+7.6%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$1.7M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-75.9%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Calculated from Citius Oncology, Inc.’s reported figures.

$1.7Mtotal revenue−$328.9Ktotal cost of revenue=$1.34M

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s gross profit?: Citius Oncology, Inc. (CTOR) reported gross profit of $1.34M in Q1 2026.
What does gross profit mean?: Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.